BriaCell Therapeutics Corp. - BCTX STOCK NEWS

BriaCell Therapeutics presented promising clinical efficacy data for its lead candidate, Bria-IMT™, at the ASCO 2024 meeting. The therapy showed a significant increase in Progression-Free Survival (PFS) and Clinical Benefit Rate (CBR) compared to historical treatments. The therapy was well-tolerated with no related discontinuations. The Phase 2 study included 54 heavily pretreated metastatic breast cancer patients, showing a median PFS of 4.1 months, nearly double the rate of similar studies. Dr. Saranya Chumsri and Dr. Carmen Calfa highlighted the potential for Bria-IMT™ to address unmet medical needs in advanced breast cancer. Further, BriaCell's pivotal Phase 3 study will compare Bria-IMT™ with Treatment of Physician's Choice (TPC).

BriaCell Therapeutics (NASDAQ: BCTX, BCTXW; TSX: BCT), a clinical-stage biotechnology company, has initiated a first-in-human Phase 1/2 study for its immunotherapy, Bria-OTS™, targeting advanced metastatic breast cancer. The study aims to evaluate the safety and efficacy of Bria-OTS™ both as a monotherapy and in combination with the PD-1 inhibitor tislelizumab. This milestone follows the successful completion of Institutional Review Board (IRB) and Clinical Trial Site Agreement (CTA) processes, along with FDA authorization for Investigational New Drug (IND) filings. BriaCell's leadership believes the personalized approach of Bria-OTS™ could lead to more potent and durable responses, potentially improving patients' quality of life and extending survival. The treatment's off-the-shelf nature is expected to provide rapid therapeutic intervention, important for patients with advanced metastatic breast cancer.

BriaCell Therapeutics has announced a clinical supply agreement with BeiGene to assess the safety and efficacy of BriaCell’s Bria-OTS™ immunotherapy in combination with BeiGene's anti-PD-1 antibody, tislelizumab, for treating advanced, heavily pretreated metastatic breast cancer. This Phase 1/2 trial will initially focus on Bria-OTS™ alone in breast cancer, expanding to a combination therapy with tislelizumab. BriaCell aims to extend this therapy to prostate and other cancers. The Bria-OTS™ platform builds on Bria-IMT™, which has shown benefits in patients with CNS metastases and resistance to checkpoint inhibitors and ADCs.

BriaCell Therapeutics announced promising clinical data for its lead product candidate, Bria-IMT™, at the ASCO 2024 Annual Meeting. Key results include a median progression-free survival (PFS) of 4.1 months in ADC-resistant advanced breast cancer patients, which is double the PFS of patients in similar studies. The clinical benefit rate was 55% across HR+, HER2+, and TNBC disease types. Additionally, the therapy achieved an 83% intracranial objective response rate in patients with CNS metastases. The treatment was well-tolerated with no related discontinuations or cases of interstitial lung disease. These findings will be presented through various sessions during the ASCO event held from May 31 to June 4, 2024.

BriaCell Therapeutics, a clinical-stage biotech firm, has closed a $5.0 million registered direct offering with institutional and existing investors, including a director. The offering involves the sale of 2,402,935 common shares and warrants, with each unit priced at $2.00 to $2.215. The proceeds will fund working capital, R&D, a Phase 3 breast cancer study, and legal costs. A.G.P./Alliance Global Partners acted as the sole placement agent. The offering has been conducted under an existing shelf registration statement filed with the SEC.

BriaCell Therapeutics announced a $5.0 million registered direct offering, involving the sale of 2,402,935 common shares or pre-funded warrants and warrants to institutional investors and a director. The shares are priced at $2.00 each for institutional investors and $2.215 for the director, with warrants exercisable at $2.11 within six months and expiring in five years. The proceeds will support working capital, R&D, including a Phase 3 study in advanced breast cancer, and potential share repurchases. The offering closes around May 17, 2024, subject to customary conditions.

BriaCell Therapeutics Corp. announces oral and poster presentations at ASCO 2024 by Mayo Clinic Professor Saranya Chumsri on clinical data of Bria-IMT™ in advanced metastatic breast cancer. Two posters feature collaborations with prominent medical professionals in pivotal Phase 3 study and clinical data of Bria-IMT™ in patients who failed ADCs.

BriaCell Therapeutics Corp. reports strong anti-cancer activity of Bria-OTS+™ and Bria-PROS+™ immunotherapies in breast and prostate cancer patients based on preclinical data presented at AACR 2024. The novel mechanisms of action show enhanced immune responses and activation of key immune system components, potentially leading to potent and long-lasting anti-cancer effects. The next-generation platforms aim to provide personalized, off-the-shelf, and ready-to-use therapies with improved efficacy and safety profiles.

BriaCell Therapeutics Corp. presents positive clinical data for Bria-IMT™ at AACR Annual Meeting, showcasing significant potential in managing CNS metastatic disease in advanced breast cancer. With a PFS of 4.2 months, clinical benefit rate of 56%, and 71% iORR, the findings reinforce the clinical efficacy of Bria-IMT™ in patients resistant to ADCs.